We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
-0.98%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$473M
AUM Growth
+$25.3M
Cap. Flow
+$53.8M
Cap. Flow %
11.37%
Top 10 Hldgs %
75.64%
Holding
30
New
3
Increased
11
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$16.7M
2
KURA icon
Kura Oncology
KURA
+$15.1M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$11.9M
4
ARWR icon
Arrowhead Research
ARWR
+$11.8M
5
COGT icon
Cogent Biosciences
COGT
+$9.86M

Top Sells

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$11.7M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$9.94M
3
BLU
BELLUS Health Inc.
BLU
+$9.47M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$7.86M
5
GNCA
Genocea Biosciences, Inc.
GNCA
+$3.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
2 Financials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
26
Dyne Therapeutics
DYN
$4.04B
– –
-305,125
Closed -$2.94M
MREO
27
Mereo BioPharma
MREO
$45.9M
– –
-1,954,970
Closed -$2.19M
PMVP icon
28
PMV Pharmaceuticals
PMVP
$66.1M
– –
-125,000
Closed -$2.6M
PTGX icon
29
Protagonist Therapeutics
PTGX
$8.75B
– –
-331,886
Closed -$7.86M
GNCA
30
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-3,079,756
Closed -$3.85M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Commodore Capital held 30 positions worth $473M, up 5.6% from $448M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Commodore Capital deployed $53.8M of net new capital in Q2 2022, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Arrowhead Research: 312,533 shares worth $11M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Karyopharm Therapeutics, an estimated $9.94M trimmed.

  • Commodore Capital's largest Q2 2022 buy was Arrowhead Research: 312,533 shares worth $11M.
  • Commodore Capital added most to Merus in Q2 2022, an estimated $16.7M increase.
  • Commodore Capital's biggest Q2 2022 reduction was Karyopharm Therapeutics, cutting an estimated $9.94M.
  • Commodore Capital fully exited C4 Therapeutics in Q2 2022, selling an estimated $11.7M.
  • Commodore Capital's ten largest holdings make up 76% of its $473M portfolio in Q2 2022.
  • Commodore Capital opened 3 new positions and closed 6 in Q2 2022.
  • Commodore Capital's portfolio value rose 5.6% quarter-over-quarter to $473M.

Based on Commodore Capital's 13F filing for Q2 2022, filed 15 Aug 2022.